Teleflex Incorporated a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products, driving an enhanced global presence in the cath lab.

Teleflex Incorporated 是一家全球领先的医疗技术提供商，今天宣布已完成此前宣布的对 BIOTRONIK SE & Co. KG 血管介入业务绝大部分的收购。此次收购为 Teleflex 的介入通路产品组合增添了广泛治疗产品组合，进一步增强了其在全球导管室市场的地位。

The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication..

血管介入业务还将确立 Teleflex 在快速增长的外周介入市场中的全球地位，并为目前具有外周适应症的 Teleflex 产品提供一个渠道。

On February 27, 2025, Teleflex announced its entry into a definitive agreement to acquire substantially all of BIOTRONIK’s Vascular Intervention business. Under the terms of the agreement, Teleflex acquired the Vascular Intervention business for a cash payment of €760 million, less certain adjustments as provided in the purchase agreement, including certain working capital not transferring and other customary adjustments..

2025年2月27日，Teleflex宣布已达成一项最终协议，收购BIOTRONIK大部分血管介入业务。根据协议条款，Teleflex以7.6亿欧元的现金支付收购了该血管介入业务，减去购买协议中规定的某些调整金额，包括某些不转移的营运资本及其他惯例调整。

“We are pleased to announce the completion of the acquisition of substantially all of the Vascular Intervention business of BIOTRONIK earlier than expected” said Liam Kelly, Chairman, President and Chief Executive Officer of Teleflex. “The acquisition will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care.

“我们很高兴地宣布，比预期更早完成了对BIOTRONIK大部分血管介入业务的收购，”Teleflex董事长、总裁兼首席执行官Liam Kelly表示。“此次收购将显著增强我们在导管室的全球影响力，扩大我们的创新技术组合，并改善患者护理。”

We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market. The acquired business is rooted in robust research and development, clinical expertise, and global manufacturing capabilities, which we believe will further bolster Teleflex’s innovation pipeline, and position the company to participate in the emerging potential for resorbable scaffold technologies.

我们相信，此次收购将使我们能够将这一先进的冠状动脉产品组合与我们现有的介入业务并列，并确立我们在快速增长的外周介入市场中的全球地位。所收购的业务植根于强大的研发、临床专业知识和全球制造能力，我们相信这将进一步增强Teleflex的创新渠道，并使公司能够参与可吸收支架技术新兴潜力的发展。

We will provide additional details on our second quarter earnings conference call.”.

我们将在第二季度收益电话会议上提供更多细节。”

The acquired Vascular Intervention business consists of a comprehensive and differentiated portfolio for coronary and peripheral interventions performed in the cath lab and interventional radiology suites. In coronary vascular interventions, key products include the Pantera™ Lux™ Drug-Coated Balloon Catheter, the novel PK Papyrus™ Covered Coronary Stent for acute coronary artery perforations, and the Orsiro™ Mission Drug Eluting Stent, an ultrathin drug-eluting stent with differentiated clinical features.

收购的血管介入业务包括在导管室和介入放射科进行的冠状动脉和外周介入的全面且差异化的产品组合。在冠状动脉血管介入方面，关键产品包括Pantera™ Lux™药物涂层球囊导管、用于急性冠状动脉穿孔的新型PK Papyrus™覆膜冠状动脉支架，以及Orsiro™ Mission药物洗脱支架，这是一种具有差异化临床特点的超薄药物洗脱支架。

For peripheral interventions, the portfolio includes the Passeo™-18 Lux™ Peripheral Drug-Coated Balloon Catheter, Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent, the Pulsar™-18 T3 Self-Expanding 4F Stent, and the Oscar™ peripheral multifunctional catheter system..

对于外周介入，该产品组合包括Passeo™-18 Lux™外周药物涂层球囊导管、Dynetic™-35球囊扩张钴铬合金支架、Pulsar™-18 T3自膨胀4F支架以及Oscar™外周多功能导管系统。

The acquisition of the Vascular Intervention business will also allow Teleflex the opportunity to invest in and expand the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold (RMS) technology, including plans to initiate a U.S. pivotal study. Freesolve™, which received its CE Mark in February 2024, is indicated in CE-mark accepting countries for de novo coronary artery lesions.

收购血管介入业务还将使Teleflex有机会投资并扩展Freesolve™的临床试验计划，Freesolve™是一种含西罗莫司的可吸收金属支架（RMS）技术，其中包括启动美国关键性研究的计划。Freesolve™于2024年2月获得CE认证，在接受CE标志的国家适用于新发冠状动脉病变。

The combination of temporary scaffolding with drug delivery is anticipated to address the current trend in interventional coronary and endovascular procedures toward leaving behind less permanent hardware. As demonstrated in the BIOMAG-I study, Freesolve™ RMS demonstrated resorption after 12 months, a target lesion failure rate comparable to contemporary drug-eluting stents, and no definite or probable scaffold thrombosis.1,2 The European pivotal BIOMAG-II study is now enrolling..

临时支架与药物输送的结合有望解决当前冠状动脉和血管内介入手术中减少永久性硬件残留的趋势。正如BIOMAG-I研究中所展示的，Freesolve™ RMS在12个月后显示出吸收性，目标病灶失败率与当代药物洗脱支架相当，并且没有明确或可能的支架血栓形成。欧洲关键性的BIOMAG-II研究现在正在招募患者。

Vascular Intervention Acquisition Financial Outlook

血管介入收购财务展望

Given the earlier than expected completion of the Vascular Intervention acquisition, we now expect the acquired products to generate revenues of €177 million in the second half of 2025 or $204 million. As previously disclosed, we expect the acquired products to generate €91 million in revenues for the fourth quarter of 2025 or $105 million.

鉴于血管介入收购的完成时间早于预期，我们现在预计收购的产品将在2025年下半年产生1.77亿欧元的收入，即2.04亿美元。正如之前披露的，我们预计收购的产品将在2025年第四季度产生9,100万欧元的收入，即1.05亿美元。

Beginning in 2026, we expect sales of the acquired products to deliver annual constant currency revenue growth of 6% or better..

自2026年起，我们预计收购产品的销售额将实现每年6%或更高的固定汇率收入增长。

Excluding non-recurring purchase accounting items and other acquisition and integration related costs, the transaction is still expected to be approximately $0.10 accretive to the Company’s adjusted earnings per share in the first year of ownership, and to be increasingly accretive, thereafter.

排除非经常性采购会计项目及其他收购和整合相关成本，该交易预计在第一年持有期内，仍将使公司的调整后每股收益增加约0.10美元，并在此后逐渐增加。

About Teleflex Incorporated

关于Teleflex公司

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology.

作为一家全球医疗技术提供商，Teleflex 的使命是改善人们的健康和生活质量。我们以成为医疗领域最受信赖的合作伙伴为愿景，提供涵盖麻醉、急诊医学、介入心脏病学与放射学、外科、血管通路和泌尿科治疗领域的多样化解决方案组合。

We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare..

我们相信，优秀的人才、目标驱动的创新和世界级的产品有潜力塑造医疗保健的未来方向。

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

Teleflex 是 Arrow™、Barrigel™、Deknatel™、LMA™、Pilling™、QuikClot™、Rüsch™、UroLift™ 和 Weck™ 的所在地——这些值得信赖的品牌因共同的目标而联合在一起。

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

在Teleflex，我们正在赋能医疗保健的未来。欲了解更多信息，请访问teleflex.com。

Not all products may be available in all countries. The above-referenced drug-coated devices are not available in the United States and Japan.

并非所有产品都会在所有国家/地区提供。上述药物涂层设备无法在美国和日本提供。

References

参考文献

:

：

Seguchi M, Aytekin A, Xhepa E, Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Waksman R, Garcia-Garcia HM, Joner M. Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study.

Seguchi M, Aytekin A, Xhepa E, Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Waksman R, Garcia-Garcia HM, Joner M. 第三代药物洗脱可吸收冠状动脉镁支架植入后的血管反应：BIOMAG-I首次人体研究的血管内成像分析。

EuroIntervention. 2024 Sep 16;20(18):e1173-e1183. doi: 10.4244/EIJ-D-24-00055. PMID: 39279514; PMCID: PMC11384225. The study was sponsored by BIOTRONIK. M. Seguchi, M. Haude, J.F. Iglesias, J. Bennett, G.G. Toth, M. Wiemer, G. Olivecrona, R. Waksman, H.M. Garcia-Garcia, and M. Joner are paid consultants of BIOTRONIK. .

EuroIntervention. 2024年9月16日；20(18):e1173-e1183. doi: 10.4244/EIJ-D-24-00055. PMID: 39279514; PMCID: PMC11384225. 本研究由BIOTRONIK赞助。M. Seguchi、M. Haude、J.F. Iglesias、J. Bennett、G.G. Toth、M. Wiemer、G. Olivecrona、R. Waksman、H.M. Garcia-Garcia和M. Joner为BIOTRONIK的付费顾问。

Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Joner M, Toelg R, Wiemer M, Olivecrano G, Vermeersch P, Garcia-Garcia HM, Waksman R. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.

Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Joner M, Toelg R, Wiemer M, Olivecrano G, Vermeersch P, Garcia-Garcia HM, Waksman R. 一种用于新发冠状动脉病变的新型可吸收镁支架（DREAMS 3）：BIOMAG-I首次人体研究的一年结果。

EuroIntervention. 2023 Aug 7;19(5):e414-e422. doi: 10.4244/EIJ-D-23-00326. PMID: 37334655; PMCID: PMC10397670..

欧洲心脏病学杂志。2023年8月7日；19(5):e414-e422。doi: 10.4244/EIJ-D-23-00326。PMID: 37334655；PMCID: PMC10397670。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements, including, but not limited to, statements about our acquisition of the Vascular Intervention business, our and the Vascular Intervention business’s commercialized and pipeline products, and the Vascular Intervention business’s technology platform, including, in each case, their potential benefits, anticipated revenue contribution, and anticipated adjusted earnings per share accretion.

本新闻稿包含前瞻性陈述，包括但不限于关于我们收购血管介入业务、我们和血管介入业务的已上市及在研产品，以及血管介入业务的技术平台的陈述，包括在每种情况下它们的潜在益处、预期收入贡献和预期调整后每股收益增益。

Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; customer and shareholder reaction to the transaction; risks associated with the completed financing of the transaction; disruption from the transaction making it more difficult to maintain business and operational relationships; significant transaction costs; unknown liabilities; the risk of regulatory actions related to the acquisition; changes in general and international economic conditions, including fluctuations in foreign currency exchange rates; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2024..

由于各种原因，实际结果可能与前瞻性陈述中的结果存在重大差异，这些原因包括但不限于：与整合计划相关的意外困难和支出；客户和股东对本次交易的反应；与已完成的交易融资相关的风险；交易带来的业务和运营关系维护难度增加；重大的交易成本；未知的负债；与收购相关的监管行动风险；一般和国际经济状况的变化，包括外汇汇率的波动；以及我们向证券交易委员会提交的文件中描述或包含的其他因素，包括截至2024年12月31日的年度Form 10-K报告。

CAUTION: Federal (USA) law restricts these devices for sale or use by or on the order of a physician.

注意：美国联邦法律规定，这些设备的销售或使用仅限于医生或根据医生的指示进行。

Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Titan SGS, Rüsch, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. Other names are the trademarks of their respective owners. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions.

Teleflex、Teleflex标志、Arrow、Barrigel、Deknatel、LMA、Pilling、QuikClot、Titan SGS、Rüsch、UroLift和Weck是Teleflex公司或其关联公司在美国和/或其他国家的商标或注册商标。其他名称为其各自所有者的商标。有关适应症、禁忌症、警告和注意事项的完整列表，请参阅使用说明书。

Information in this document is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative. .

本文件中的信息不能替代产品使用说明书。并非所有产品都在所有国家/地区提供。请联系您当地的代表。

© 2025 Teleflex Incorporated. All rights reserved.

© 2025 Teleflex Incorporated. 保留所有权利。

Contacts

联系人

:

：

Teleflex

电液

Lawrence Keusch

劳伦斯·库希

Vice President, Investor Relations and Strategy Development

副总裁，投资者关系与战略发展

[email protected]

[email protected]

610-948-2836

610-948-2836

Source: teleflex.com

来源：teleflex.com